Header
Novartis 2024 Financial Results
January 31, 2025
Basel, Switzerland
Novartis announces the company’s fourth quarter and 2024 full year financial results.

Novartis in Society Integrated Report 2024
The Novartis in Society Integrated Report provides an overview our business, strategy and performance, and describes how we create sustainable value for stakeholders and society.

Annual Report 2024 and US Securities & Exchange Commission Form 20-F 2024
These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US.
Annual Report 2024 (PDF 3.5 MB) | Form 20-F 2024 (PDF 3.4 MB)
Novartis Pipeline
Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines.
Executive Committee of Novartis (ECN) biographies
Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the business operations of Group companies.